ImmunoPrecise Antibodies Ltd. Files 6-K
Ticker: HYFT · Form: 6-K · Filed: Aug 27, 2025 · CIK: 1715925
Sentiment: neutral
Topics: reporting, foreign-private-issuer, press-release
TL;DR
IPA files 6-K, press release attached, more info to come.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on August 27, 2025, reporting a press release dated August 27, 2025. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The press release details are not included in this excerpt.
Why It Matters
This filing serves as an update for investors regarding the company's reporting status and upcoming disclosures, though specific operational or financial details are not provided in this document.
Risk Assessment
Risk Level: low — This is a routine filing that primarily serves to attach a press release, with no immediate new financial or operational information presented.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the 6-K report
- August 27, 2025 (date) — Date of the press release and filing
- Jennifer Bath (person) — Signatory for ImmunoPrecise Antibodies Ltd.
- Form 20-F (document) — Annual report form the company will file
- Form 6-K (document) — Type of report filed
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release dated August 27, 2025, as required for foreign private issuers.
Which annual report form does ImmunoPrecise Antibodies Ltd. indicate it will file?
ImmunoPrecise Antibodies Ltd. indicates it will file annual reports under cover of Form 20-F.
Who signed this report on behalf of ImmunoPrecise Antibodies Ltd.?
Jennifer Bath signed this report on behalf of ImmunoPrecise Antibodies Ltd.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is August 27, 2025.
What is the Commission File Number for ImmunoPrecise Antibodies Ltd.?
The Commission File Number for ImmunoPrecise Antibodies Ltd. is 001-39530.
Filing Stats: 144 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2025-08-27 09:49:34
Filing Documents
- press_release_august_27_.htm (6-K) — 25KB
- ipa-ex99_1.htm (EX-99.1) — 22KB
- 0000950170-25-111598.txt ( ) — 48KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: August 27, 2025 By: /s/ Jennifer Bath Name: Jennifer Bath Title: President and Chief Executive Officer